Dallas, Texas 05/28/2014 (FINANCIALSTRENDS) – Idera Pharmaceuticals Inc. (NASDAQ:IDRA), a clinical stage company, recently reported its 1Q14 financial results for the quarter ended March 31, 2014. The company reported net loss of $9.1 million ($0.12 per diluted share), for 1Q14 as compared to a net loss of $4.1 million ($0.15 per diluted share) for the same prior year quarter. The company noted nominal revenues for both 1Q14 and 1Q13.
Idera Pharmaceuticals’ 1Q14 research and development expenses increased to $6.9 million as compared to $2.3 million for 1Q13. General and administrative expenses for 1Q14 increased to $2 million as compared to $1.5 million for 1Q13. The company reported cash and cash equivalents and investments of $70.6 million as at March 31, 2014 as compared to $35.6 million as at December 31, 2013. During 1Q14 the company also announced gross proceeds of $40.1 million from its underwritten public offering in February 2014.
Chief Financial Officer of Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Lou Arcudi mentioned to have ended 1Q14 with a strong financial position, ensuring adequate resources to advance the company’s clinical and pre-clinical programs and meet its near term business objectives.
The Chief Executive Officer of the company, Sudhir Agrawal mentioned that company initiated clinical development for its IMO-8400 and the company looks forward to progress this candidate in clinical trials for its diffuse large B-cell lymphoma and Waldenstrom’s macroglobulinemia indications.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) also strengthened its management team to better pursue clinical development of its pipeline portfolio. The company announced appointment of Lou Brenner as its SVP and Chief Medical Officer; Kate Haviland as VP for Rare Diseases; Nancy Wyant as VP for Clinical Operations; and Joe Lobacki as GM of Oncology, among others.
Yesterday, the stock of the company gained 3.56% and closed at $2.62. The stock has delivered 37.62% negative returns year to date.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.